Seeking Alpha

An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via...

An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector